SeaStar Medical

Historical price data

SeaStar Medical is executing a mission to transform outcomes for critically ill patients suffering from hyperinflammatory conditions like cytokine storm. Its key achievement is the FDA approval and commercial launch of Quelimmune, a pediatric therapy approved under a Humanitarian Device Exemption. The company's strategy leverages its proprietary SCD platform across multiple high-need adult critical care indications, supported by FDA Breakthrough Device Designations, aiming to address a multi-billion dollar market with a disease-modifying therapeutic approach.

The Selective Cytopheretic Device (SCD) is an extracorporeal blood purification cartridge that selectively binds and deactivates highly activated neutrophils and monocytes to modulate the immune system and halt the cytokine storm, integrating into standard ICU CRRT equipment.